Aethlon Medical price target lowered to $10 from $23 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Aethlon Medical to $10 from $23 and keeps a Buy rating on the shares. The firm says the company is continuing study of Hemopurifier use as a treatment against life-threatening viral infections in India. The analyst believes prospects for successful results in combination use are good.